GRAY MARY ANN 4

What Happened

• Mary Ann Gray, a director of Keros Therapeutics, received two compensation awards on June 3, 2026: 7,142 restricted stock units (RSUs) and a 7,433-share derivative award (an option-style grant). Both awards are reported at $0.00 per share (no cash paid). These are grants (transaction code A) — not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-03; Form 4 filed 2026-06-05 (timely).
• Award amounts and reported prices: 7,142 RSUs @ $0.00; 7,433 derivative award units @ $0.00.
• Vesting (from filing footnotes):
  • RSUs (F1): fully vest on the earlier of June 3, 2027 or the issuer’s 2027 annual meeting, subject to continued service.
  • Derivative/option (F2): vests in equal quarterly installments over the 12 months after June 3, 2026, and will be fully vested by the 2027 annual meeting, subject to continued service.
• Shares owned after the transaction: not specified in the filing.
• Filing status: timely (no late-filing indication).

Context

• RSUs convert into actual shares upon vesting; the derivative award appears to be an option-like grant that must vest before exercise. Neither award represents an immediate sale or purchase of open-market stock — they are compensation. Such grants are common for directors and are tied to continued service rather than an explicit buy/sell signal.